Publication Name	World Journal of Diabetes
Manuscript ID	40441
Country	Japan

Received	2018-06-25 00:04
Peer-Review Started	2018-06-25 03:23
To Make the First Decision	2018-07-09 08:07
Return for Revision	2018-07-11 01:59
Revised	2018-07-12 09:41
Second Decision	2018-08-22 07:00
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2018-08-26 23:46
Articles in Press	2018-08-26 23:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2018-10-09 02:55
Publish the Manuscript Online	2018-10-12 11:58

ISSN	1948-9358 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Endocrinology & Metabolism
Manuscript Type	Retrospective Cohort Study
Article Title	Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study
Manuscript Source	Invited Manuscript
All Author List	Hidetaka Hamasaki and Yasuteru Hamasaki
ORCID	Author(s) ORCID Number Hidetaka Hamasaki http://orcid.org/0000-0002-0124-597X Yasuteru Hamasaki http://orcid.org/0000-0002-1522-0132
Funding Agency and Grant Number
Corresponding Author	Hidetaka Hamasaki, MD, PhD, Doctor, Doctor, Endocrinology and Metabolism, Internal Medicine, Hamasaki Clinic, 2-21-4 Nishida, Kagoshima 8900046, Japan. hhamasaki78@gmail.com
Key Words	Type 2 diabetes mellitus; Dipeptidyl pep­tidase-4 inhibitor; Anagliptin; Linagliptin; Cholesterol
Core Tip	Whether a substantial clinical difference exists in the effect of dipeptidyl peptidase-4 (DPP-4) inhibitors on metabolic parameters remains inconclusive. Although this study is a relatively small-scale, short duration, retrospective study, the findings of this study suggests that the efficacy of DPP-4 inhibitors on the blood pressure, lipid profile, and liver function differs between anagliptin and linagliptin.
Publish Date	2018-10-12 11:58
Citation	Hamasaki H, Hamasaki Y. Efficacy of anagliptin as compared to linagliptin on metabolic parameters over 2 years of drug consumption: A retrospective cohort study. World J Diabetes 2018; 9(10): 165-171
URL	http://www.wjgnet.com/1948-9358/full/v9/i10/165.htm
DOI	http://dx.doi.org/10.4239/wjd.v9.i10.165

Full Article (PDF)	WJD-9-165.pdf
Full Article (Word)	WJD-9-165.doc
STROBE Statement	40441-STROBE statement.pdf
Manuscript File	40441-Review.docx
Answering Reviewers	40441-Answering reviewers.pdf
Audio Core Tip	40441-Audio core tip.m4a
Biostatistics Review Certificate	40441-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	40441-Conflict-of-interest statement.pdf
Copyright License Agreement	40441-Copyright license agreement.pdf
Institutional Review Board Approval Form or Document	40441-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	40441-Language certificate.pdf
Peer-review Report	40441-Peer-review(s).pdf
Scientific Misconduct Check	40441-Scientific misconduct check.pdf
Scientific Editor Work List	40441-Scientific editor work list.pdf